[SCHEDULE 13G] Myriad Genetics Inc SEC Filing
Barclays PLC reported beneficial ownership of 4,899,951 shares of Myriad Genetics common stock, equal to 5.31% of the class. The filing shows Barclays has sole voting and dispositive power over 4,762,680 shares and shared voting and dispositive power over 137,271 shares. The reporting person is classified as HC and the filing identifies related subsidiaries as Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
This document is a Schedule 13G disclosure and includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence the control of the issuer.
Barclays PLC ha dichiarato la propriet脿 effettiva di 4,899,951 azioni ordinarie di Myriad Genetics, pari al 5.31% della classe. La comunicazione indica che Barclays detiene il potere di voto e di disposizione esclusivo su 4,762,680 azioni e il potere di voto e di disposizione congiunto su 137,271 azioni. La persona che effettua la comunicazione 猫 classificata come HC e il deposito segnala le controllate correlate come Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
Il documento 猫 una comunicazione Schedule 13G e contiene una certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attivit脿 e non sono stati acquistati per modificare o influenzare il controllo dell'emittente.
Barclays PLC declar贸 la propiedad beneficiaria de 4,899,951 acciones ordinarias de Myriad Genetics, equivalentes al 5.31% de la clase. El documento indica que Barclays tiene poder de voto y de disposici贸n exclusivo sobre 4,762,680 acciones y poder de voto y de disposici贸n compartido sobre 137,271 acciones. La persona informante est谩 clasificada como HC y el informe identifica a las filiales relacionadas como Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
Este documento es una declaraci贸n Schedule 13G e incluye una certificaci贸n de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no se adquirieron para cambiar o influir en el control del emisor.
Barclays PLC電� Myriad Genetics 氤错喌欤� 4,899,951欤�(頃措嫻 韥措灅鞀れ潣 5.31%)鞐� 雽�頃� 鞁れ唽鞙犼秾鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� Barclays電� 4,762,680欤检棎 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃, 137,271欤检棎 雽�頃挫劀電� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 臧�歆�瓿� 鞛堨姷雼堧嫟. 氤搓碃鞚胳潃 HC搿� 攵勲霅橂┌ 鞝滌稖靹滊電� 甏�霠� 鞛愴殞靷 Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd毳� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
鞚� 氍胳劀電� Schedule 13G 瓿奠嫓搿�, 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑路氤挫湢霅橃棃鞙茧┌ 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Barclays PLC a d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 4,899,951 actions ordinaires de Myriad Genetics, soit 5.31% de la cat茅gorie. Le d茅p么t indique que Barclays dispose du pouvoir de vote et de disposition exclusif sur 4,762,680 actions et du pouvoir de vote et de disposition partag茅 sur 137,271 actions. La personne d茅clarante est class茅e comme HC et le d茅p么t identifie les filiales concern茅es comme Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
Ce document est une d茅claration Schedule 13G et comprend une attestation que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et n'ont pas 茅t茅 acquis en vue de modifier ou d'influencer le contr么le de l'茅metteur.
Barclays PLC meldete wirtschaftliches Eigentum an 4,899,951 Stammaktien von Myriad Genetics, was 5.31% der Klasse entspricht. Die Einreichung weist aus, dass Barclays alleinige Stimm- und Verf眉gungsgewalt 眉ber 4,762,680 Aktien und gemeinsame Stimm- und Verf眉gungsgewalt 眉ber 137,271 Aktien hat. Die meldende Person ist als HC klassifiziert, und in der Einreichung werden verbundene Tochtergesellschaften als Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd genannt.
Dieses Dokument ist eine Schedule鈥�13G鈥慐rkl盲rung und enth盲lt die Best盲tigung, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverlauf erworben und gehalten wurden und nicht dazu bestimmt waren, die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
- Material disclosed stake: Barclays PLC beneficially owns 4,899,951 shares, representing 5.31% of Myriad Genetics common stock.
- Clear voting/dispositive control figures: Sole voting and dispositive power reported for 4,762,680 shares and shared power for 137,271 shares.
- None.
Insights
TL;DR: Barclays holds a material 5.31% stake in Myriad Genetics with substantial sole voting and dispositive power.
The filing reports 4,899,951 shares beneficially owned representing 5.31% of the class. Of those, Barclays reports sole voting and dispositive power over 4,762,680 shares and shared power over 137,271 shares. As a Schedule 13G, the statement emphasizes ordinary-course holding rather than an intent to influence control, with the reporting person classified as HC and related subsidiaries identified. For investors, the entry of a large financial institution as a >5% holder is a material ownership disclosure but the filing expressly disclaims a control purpose.
TL;DR: Disclosure shows a significant institutional stake but includes a certification denying intent to alter issuer control.
The Schedule 13G lists Barclays PLC as beneficial owner of 4,899,951 shares (5.31%) and identifies subsidiaries involved in the holding. The filing includes explicit certification language that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The reporting-person classification HC and the voting/dispositive figures are clearly stated, enabling governance analysis based on exact ownership and control metrics provided in this filing.
Barclays PLC ha dichiarato la propriet脿 effettiva di 4,899,951 azioni ordinarie di Myriad Genetics, pari al 5.31% della classe. La comunicazione indica che Barclays detiene il potere di voto e di disposizione esclusivo su 4,762,680 azioni e il potere di voto e di disposizione congiunto su 137,271 azioni. La persona che effettua la comunicazione 猫 classificata come HC e il deposito segnala le controllate correlate come Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
Il documento 猫 una comunicazione Schedule 13G e contiene una certificazione che i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attivit脿 e non sono stati acquistati per modificare o influenzare il controllo dell'emittente.
Barclays PLC declar贸 la propiedad beneficiaria de 4,899,951 acciones ordinarias de Myriad Genetics, equivalentes al 5.31% de la clase. El documento indica que Barclays tiene poder de voto y de disposici贸n exclusivo sobre 4,762,680 acciones y poder de voto y de disposici贸n compartido sobre 137,271 acciones. La persona informante est谩 clasificada como HC y el informe identifica a las filiales relacionadas como Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
Este documento es una declaraci贸n Schedule 13G e incluye una certificaci贸n de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no se adquirieron para cambiar o influir en el control del emisor.
Barclays PLC電� Myriad Genetics 氤错喌欤� 4,899,951欤�(頃措嫻 韥措灅鞀れ潣 5.31%)鞐� 雽�頃� 鞁れ唽鞙犼秾鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� Barclays電� 4,762,680欤检棎 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃, 137,271欤检棎 雽�頃挫劀電� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 臧�歆�瓿� 鞛堨姷雼堧嫟. 氤搓碃鞚胳潃 HC搿� 攵勲霅橂┌ 鞝滌稖靹滊電� 甏�霠� 鞛愴殞靷 Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd毳� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
鞚� 氍胳劀電� Schedule 13G 瓿奠嫓搿�, 歃濌秾鞚� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑路氤挫湢霅橃棃鞙茧┌ 氚滍枆鞚胳潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Barclays PLC a d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 4,899,951 actions ordinaires de Myriad Genetics, soit 5.31% de la cat茅gorie. Le d茅p么t indique que Barclays dispose du pouvoir de vote et de disposition exclusif sur 4,762,680 actions et du pouvoir de vote et de disposition partag茅 sur 137,271 actions. La personne d茅clarante est class茅e comme HC et le d茅p么t identifie les filiales concern茅es comme Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
Ce document est une d茅claration Schedule 13G et comprend une attestation que les titres ont 茅t茅 acquis et sont d茅tenus dans le cours normal des affaires et n'ont pas 茅t茅 acquis en vue de modifier ou d'influencer le contr么le de l'茅metteur.
Barclays PLC meldete wirtschaftliches Eigentum an 4,899,951 Stammaktien von Myriad Genetics, was 5.31% der Klasse entspricht. Die Einreichung weist aus, dass Barclays alleinige Stimm- und Verf眉gungsgewalt 眉ber 4,762,680 Aktien und gemeinsame Stimm- und Verf眉gungsgewalt 眉ber 137,271 Aktien hat. Die meldende Person ist als HC klassifiziert, und in der Einreichung werden verbundene Tochtergesellschaften als Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd genannt.
Dieses Dokument ist eine Schedule鈥�13G鈥慐rkl盲rung und enth盲lt die Best盲tigung, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverlauf erworben und gehalten wurden und nicht dazu bestimmt waren, die Kontrolle des Emittenten zu 盲ndern oder zu beeinflussen.
FAQ
How many Myriad Genetics (MYGN) shares does Barclays PLC beneficially own?
What percentage of MYGN does Barclays' stake represent?
How much voting power does Barclays report for its MYGN holdings?
Is the Barclays stake reported as intended to influence control of Myriad Genetics (MYGN)?
Which Barclays entities are identified in the Schedule 13G for this holding?
What type of SEC filing reports this ownership?
